Product Code: ETC13335254 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Non-Alcoholic Fatty Liver Disease Market was valued at USD 3.6 Billion in 2024 and is expected to reach USD 5.2 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The Global Non-Alcoholic Fatty Liver Disease (NAFLD) market is experiencing significant growth due to the rising prevalence of obesity and metabolic disorders worldwide. NAFLD is the most common liver disorder, characterized by the accumulation of fat in the liver without excessive alcohol consumption. The market is driven by the increasing awareness of NAFLD among healthcare professionals and patients, leading to early diagnosis and treatment initiation. Therapeutic options for NAFLD include lifestyle modifications, pharmacotherapy, and surgical interventions in severe cases. The market is also witnessing a surge in research and development activities to develop novel treatment options targeting the underlying mechanisms of the disease. Overall, the Global NAFLD market is poised for continued growth as the prevalence of obesity and associated comorbidities continues to rise globally.
The Global Non-Alcoholic Fatty Liver Disease (NAFLD) market is experiencing significant growth due to the increasing prevalence of obesity and sedentary lifestyles worldwide. The market is driven by the rising awareness about the disease and its potential complications, leading to a higher demand for diagnostic tools and treatment options. Opportunities in the market include the development of novel therapeutic approaches, such as targeting specific pathways involved in NAFLD pathogenesis, as well as the introduction of non-invasive diagnostic techniques. Additionally, the market is witnessing a surge in research and development activities focused on identifying biomarkers for early detection and monitoring of NAFLD progression. Overall, the market is poised for continued expansion as healthcare systems prioritize the management of metabolic disorders and liver diseases.
The Global Non-Alcoholic Fatty Liver Disease (NAFLD) market faces several challenges, including the lack of specific diagnostic tools and treatment options, the heterogeneity of the disease, and the limited understanding of its underlying mechanisms. Additionally, the rising prevalence of NAFLD worldwide poses a significant economic burden on healthcare systems. Clinical trials for NAFLD treatments often face challenges in patient recruitment and retention, as well as the lack of validated biomarkers to measure treatment efficacy. Regulatory hurdles and the need for long-term safety data also present obstacles in bringing new therapies to market. Overall, addressing these challenges will be crucial in advancing the development of effective treatments for NAFLD and improving outcomes for patients.
The global non-alcoholic fatty liver disease market is predominantly driven by the increasing prevalence of obesity and related metabolic disorders, such as diabetes and hypertension, which are significant risk factors for the development of fatty liver disease. Lifestyle changes leading to unhealthy diets, sedentary lifestyles, and rising alcohol consumption are also contributing factors. Additionally, the growing awareness among both healthcare professionals and patients about the potential complications and consequences of fatty liver disease is driving the demand for diagnostic tools and treatment options. Moreover, the rise in research and development activities focused on innovative therapies and drug development for non-alcoholic fatty liver disease is expected to further propel the market growth in the coming years.
Government policies related to the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market focus on promoting public awareness, implementing preventive measures, and enhancing healthcare infrastructure. Countries are investing in educational campaigns to raise awareness about the risks associated with NAFLD, encouraging healthy lifestyle choices to prevent the disease. Additionally, governments are implementing regulations to reduce the consumption of sugary beverages and fatty foods, which are major contributors to NAFLD. Healthcare systems are being strengthened to improve early detection, diagnosis, and treatment of NAFLD through increased funding for research, training healthcare professionals, and expanding access to specialized care for patients. Overall, government policies are aimed at addressing the growing burden of NAFLD by prioritizing prevention, early intervention, and improving healthcare services to effectively manage this public health issue.
The Global Non-Alcoholic Fatty Liver Disease (NAFLD) market is expected to witness significant growth in the coming years, driven by the rising prevalence of obesity and other metabolic disorders worldwide. The increasing awareness about the disease, advancements in diagnostic techniques, and a growing pipeline of novel treatment options are anticipated to contribute to market expansion. Additionally, government initiatives aimed at addressing the disease burden and improving healthcare infrastructure are likely to further boost market growth. However, challenges such as limited availability of effective treatment options and high costs associated with the management of NAFLD may hinder market growth to some extent. Overall, the Global NAFLD market is poised for expansion, offering opportunities for pharmaceutical companies, healthcare providers, and stakeholders to address the unmet needs of patients with this condition.
In the global non-alcoholic fatty liver disease (NAFLD) market, Asia is anticipated to witness significant growth due to the rising prevalence of obesity and metabolic disorders in countries like China and India. North America is expected to dominate the market owing to the high awareness levels, advanced healthcare infrastructure, and increasing research activities in the region. Europe is also a key market, driven by the growing adoption of sedentary lifestyles and unhealthy dietary habits. The Middle East and Africa region is projected to experience steady growth due to the rising incidence of diabetes and obesity-related conditions. In Latin America, the market is expected to expand due to improving healthcare infrastructure and increasing awareness about NAFLD among the population. Overall, the global NAFLD market is characterized by regional variations in terms of prevalence rates, healthcare infrastructure, and awareness levels.
Global Non-Alcoholic Fatty Liver Disease Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Non-Alcoholic Fatty Liver Disease Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 & 2031F |
3.3 Global Non-Alcoholic Fatty Liver Disease Market - Industry Life Cycle |
3.4 Global Non-Alcoholic Fatty Liver Disease Market - Porter's Five Forces |
3.5 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume Share, By Diagnosis Method, 2021 & 2031F |
3.8 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume Share, By Treatment Approach, 2021 & 2031F |
3.9 Global Non-Alcoholic Fatty Liver Disease Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Non-Alcoholic Fatty Liver Disease Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Non-Alcoholic Fatty Liver Disease Market Trends |
6 Global Non-Alcoholic Fatty Liver Disease Market, 2021 - 2031 |
6.1 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Simple NAFLD, 2021 - 2031 |
6.1.3 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Advanced NAFLD, 2021 - 2031 |
6.1.4 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Non-Alcoholic Steatohepatitis, 2021 - 2031 |
6.1.5 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Progressive NAFLD, 2021 - 2031 |
6.2 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Imaging Techniques, 2021 - 2031 |
6.2.3 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Blood Tests, 2021 - 2031 |
6.2.4 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Liver Biopsy, 2021 - 2031 |
6.2.5 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Genetic Testing, 2021 - 2031 |
6.3 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Lifestyle Modification, 2021 - 2031 |
6.3.3 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Medications, 2021 - 2031 |
6.3.4 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Clinical Trials, 2021 - 2031 |
6.3.5 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Combination Therapy, 2021 - 2031 |
6.4 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.4.4 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Research Institutes, 2021 - 2031 |
6.4.5 Global Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Pharma Companies, 2021 - 2031 |
7 North America Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
7.1 North America Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
7.2 North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
7.5 North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
7.6 North America Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
8.1 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
8.4 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
8.5 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
8.6 Latin America (LATAM) Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
9.1 Asia Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
9.4 Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
9.5 Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
9.6 Asia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
10.1 Africa Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
10.4 Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
10.5 Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
10.6 Africa Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
11.1 Europe Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
11.4 Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
11.5 Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
11.6 Europe Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Non-Alcoholic Fatty Liver Disease Market, Overview & Analysis |
12.1 Middle East Non-Alcoholic Fatty Liver Disease Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Type, 2021 - 2031 |
12.4 Middle East Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Diagnosis Method, 2021 - 2031 |
12.5 Middle East Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By Treatment Approach, 2021 - 2031 |
12.6 Middle East Non-Alcoholic Fatty Liver Disease Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Non-Alcoholic Fatty Liver Disease Market Key Performance Indicators |
14 Global Non-Alcoholic Fatty Liver Disease Market - Export/Import By Countries Assessment |
15 Global Non-Alcoholic Fatty Liver Disease Market - Opportunity Assessment |
15.1 Global Non-Alcoholic Fatty Liver Disease Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Non-Alcoholic Fatty Liver Disease Market Opportunity Assessment, By Type, 2021 & 2031F |
15.3 Global Non-Alcoholic Fatty Liver Disease Market Opportunity Assessment, By Diagnosis Method, 2021 & 2031F |
15.4 Global Non-Alcoholic Fatty Liver Disease Market Opportunity Assessment, By Treatment Approach, 2021 & 2031F |
15.5 Global Non-Alcoholic Fatty Liver Disease Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Non-Alcoholic Fatty Liver Disease Market - Competitive Landscape |
16.1 Global Non-Alcoholic Fatty Liver Disease Market Revenue Share, By Companies, 2024 |
16.2 Global Non-Alcoholic Fatty Liver Disease Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |